Key result
UltiSynq CSP ICD lead achieves a ~98% 3-month major complication-free rate, exceeding performance goals.
Why the study?
Use of ICD leads for left bundle branch area pacing has relied on adapting conventional leads not designed for conduction system pacing.
Does a purpose-built CSP ICD lead provide safe and effective left bundle branch area pacing in patients undergoing de novo ICD or CRT-D implantation?
Does a purpose-built CSP ICD lead provide safe and effective left bundle branch area pacing in patients undergoing de novo ICD or CRT-D implantation?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I think the era of high voltage leads in the left bundle area is likely upon us. We showed that these leads can be placed in the deep septum and pace the left bundle without losing ability to defibrillate the heart. So that's the best of both worlds.”
“The point of this lead was to build an ICD lead that can reliably defibrillate but that can also pace the left bundle and get into the septum. So this was designed off the optisure platform which is a commercially available Abbott lead with some modifications. They made the helix a little bit longer and they fixed the helix which is consistent with most uh uh uh Brady leads that people that people like for left bundle pacing.”
A novel, purpose-built conduction system pacing ICD lead demonstrated high implant success, stable electrical performance, and favorable short-term safety for left bundle branch area pacing.
BACKGROUND: Use of implantable cardioverter defibrillator (ICD) leads for left bundle branch area pacing (LBBAP) has relied on adaptation of conventional leads not designed for conduction system pacing (CSP). OBJECTIVE: This study aimed to evaluate the safety and effectiveness of a purpose-built CSP ICD lead designed for implantation within the LBBA. METHODS: The ASCEND CSP Investigational Device Exemption (IDE) trial is a prospective, multicenter, global, single arm, pivotal trial evaluating the UltiSynq CSP ICD lead (Model LDA1122Q) in patients undergoing de novo ICD or cardiac resynchronization therapy defibrillator (CRT-D) implantation. The primary safety end point was freedom from lead-related serious adverse device effects through 3 months, compared with a pre-specified performance goal of 88%. The primary effectiveness end point was the 3-month composite success rate of acceptable pacing capture threshold and R-wave sensing amplitude, with a performance goal of 80%. Defibrillation testing success was assessed in a pre-specified cohort. RESULTS: Among 205 implant attempts, 202 patients (98.5%), had successful lead implantation, with LBBAP criteria met in 99.0%. Among these, LBBP or likely LBBP capture criteria were met in 86.0%. The 3-month major complication-free rate was 97.5% and the primary effectiveness end point was achieved in 94.6%, exceeding both safety and effectiveness performance goals. Defibrillation testing was successful in 100%, with 92.5% defibrillated with a single 20 J shock. Lead electrical performance remained stable through 3 months. CONCLUSION: In this pivotal IDE trial, a dedicated bipolar CSP ICD lead demonstrated high implant success, stable electrical performance, reliable defibrillation efficacy, and favorable short-term safety. Longer-term follow-up is warranted to confirm durability and sustained clinical benefit.
No takes yet. Share an insight, caveat, or question.
Schaller et al. (2026) studied Patients undergoing de novo ICD or CRT-D implantation (n=202). UltiSynq CSP ICD lead (Model LDA1122Q) vs. Pre-specified performance goals was evaluated on Freedom from lead-related serious adverse device effects through 3 months. The UltiSynq CSP ICD lead achieved a 97.5% 3-month major complication-free rate and 94.6% effectiveness success, exceeding pre-specified performance goals of 88% and 80%.
Synapse has enriched 10 related papers. Consider them for comparative context: